Hematology NewsFDA approves pembrolizumab for relapsed/refractory PMBCLJune 14, 2018Aggressive LymphomasLymphoma & Plasma Cell Disorders
Hematology TimesFDA grants pembrolizumab accelerated approval for PMBCLJune 14, 2018Lymphoma & Plasma Cell DisordersPharmacyAggressive Lymphomas
Hematology TimesIbrutinib and venetoclax combo promising in frontline CLLJune 13, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
Hematology TimesChemo-free combo provides potential first-line option for FLJune 12, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive LymphomasFollicular Lymphoma
Hematology TimesFDA approves venetoclax for CLL/SLL with or without del 17pJune 10, 2018Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin LymphomaAggressive Lymphomas
Hematology NewsFDA grants regular approval to venetoclax for CLL/SLLJune 8, 2018CLLIndolent LymphomaLeukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell Disorders
Hematology NewsVenetoclax plus ibrutinib yields encouraging MRD results in first-line CLLJune 8, 2018CLLIndolent LymphomaLeukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell Disorders
Hematology TimesPolatuzumab plus BR improves efficacy in DLBCLJune 8, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive LymphomasFollicular Lymphoma
Hematology NewsChemo-free regimen appears viable in previously untreated FLJune 7, 2018Aggressive LymphomasLymphoma & Plasma Cell DisordersFollicular Lymphoma
Oncology PracticeNovel antibody shifts ‘eat me/don’t eat me’ balance in refractory NHLJune 6, 2018Immuno-oncologyLymphoma & Plasma Cell DisordersAggressive LymphomasFollicular Lymphoma
Hematology TimesSingle-agent acalabrutinib ‘impressive’ in patients with WMJune 6, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
Oncology PracticeMRD-negative status signals better outcomes in CAR T–treated ALLJune 5, 2018Immuno-oncologyALLLeukemia, Myelodysplasia, TransplantationImmunotherapyLymphoma & Plasma Cell Disorders
Hematology TimesFDA approves first biosimilar pegfilgrastimJune 5, 2018AnemiaLeukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMultiple MyelomaPharmacy
Hematology NewsWhen is denosumab an option in myeloma?June 4, 2018Multiple MyelomaLymphoma & Plasma Cell Disorders
Hospital Physician: Hematology/OncologyAggressive B-Cell Non-Hodgkin LymphomaJune 4, 2018Lymphoma & Plasma Cell DisordersFollicular LymphomaB Cell Lymphoma
